Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Amrubicin for Recurrent SCLC Continues to Look Promising
Author
Howard (Jack) West, MD

I wrote about the drug amrubicin in a prior post, after it demonstrated provocative activity in clinical trials out of Japan that were presented at ASCO 2007. Additional result on amrubicin in previously treated ED-SCLC were presented at a NYC meeting last week, and it's continued to look very encouraging in a clinical setting in which we could really use more options.

As described in a press release, the trial in question was a randomized phase II study that enrolled patients with ED-SCLC who had initially responded to platinum-based chemo (standard treatment) and then developed evidence of progression a minimum of 90 days after completing first-line treatment (sensitive relapse, as described in a prior post). Patients enrolled were randomized in a 2:1 fashion to amrubicin, given IV for 3 days every 21 days, or the FDA-approved standard drug, topotecan (Hycamtin), given IV over 5 days, respectively.

Although the results are based on only 42 patients thus far (28 receiving amrubicin, 14 receiving topotecan), the findings are striking. First, the response rate with amrubicin is 11/28 (39%) with amrubicin, not quite the 50+% rate seen in the earlier Japanese trials, but very encouraging for previously treated patients (including two complete responses, very unexpected in the recurrent SCLC setting). Second, while it might be the case that these are more "cherry-picked" patients than you'd generally see (selection bias), the topotecan arm has demonstrated responses in 2/14 (14%) patients thus far (neither a complete response), which is perfectly fine, not underperforming and about what you'd expect.

The numbers are small and it's still early, but it was also reported that there is a median survival difference of over two months favoring amrubicin, a 33% improvement.

It's early, but amrubicin has been about the most promising light in the SCLC field, so it's great to see that it's still holding up to additional scrutiny. The big test, however, will be the phase III randomized trial in patients with recurrent ED-SCLC and either sensitive or resistant relapse. This trial is just getting off the ground and will enroll 480 patients randomized to either amrubicin or current standard Hycamtin, and it will look for a significant difference in overall survival. We'll anxiously await the results of that trial and others. Information about clinical trials with amrubicin in lung cancer is here.

Next Previous link

Previous PostNext Post

Related Content

Image
Patient Education Ambassadors 2023-24
Video
  Dr. Gladys Rodriguez and Hannah Manella, RD, discuss addressing nutritional concerns of patients who are undergoing cancer care.  
Image
Head And Neck Cancer Program
Video
Drs. Shetal Patel, Siddharth Sheth, and Jared Weiss discuss the most recent advances in head and neck cancer treatment, including curable and incurable head and neck cancers, thyroid cancers, and HPV positive and negative cancers.  

Forum Discussions

Canyil, I'm sorry your father and you are going through this. While we can't give urgent help we are her to help offer info and resources to help make the best...

Hello and welcome to Grace.  I'm sorry you're going through this worry.  It is normal to watch a small very slow-growing solid nodule with once-a-year CT scans.  Anything less than a...

Thanks you very much. So in summary the course of action taken suggested by lung specalist (re scan in 12 months) seems appropriate? And a PET at this stage is probably...

I can't say what is appropriate for you that's only something your professionals with all your information can do.  However, when someone has a solid nodule less than a cm that...

A doctor wouldn't nor shouldn't suspect a pancoast tumor with the info you've given.  It's like being in Colorado and hearing hoof beats and assuming it is zebras and not horses. ...

Hello and welcome to Grace.  I'm sorry you're worrying about this but it probably isn't cancer. 

 

From Adenocarcinoma of the lung: from BAC to the future, "GGNs with diameter...

Recent Comments

JOIN THE CONVERSATION
Canyil, I'm sorry your…
By JanineT GRACE … on
I can't say what is…
By JanineT GRACE … on
Thanks you very much. So in…
By razp on
A doctor wouldn't nor…
By JanineT GRACE … on